London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Riad Mishlawi, Hikma’s CEO, said: “I am pleased ...

Hikma Pharmaceuticals (GB:HIK) has released an update. Hikma Pharmaceuticals has decided to reappoint PricewaterhouseCoopers LLP as its external auditor starting in 2026, following a competitive ...

An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

When giving gluteal injections, it is safest to use the upper outer quadrant. The choice of site for injection must be based on good clinical judgment, using the best evidence available and ...

Nov. 7, 2024 — A new study has exposed for the first time how inhabitants of the smallest countries globally, contributing least to climate change, already bear the ...

Dividend amount and dividend per share are quoted in the currency of the stock selected. Please note that past performance is not a reliable indicator of future returns. Important Information Please ...

Part of the machine shop cell inside Elnik’s new HQ (Courtesy Elnik Systems) Vacuum debinding and sintering furnaces from Elnik Systems LLC are a common sight in Metal Injection Moulding plants ...

Hikma Pharmaceuticals PLC develops, manufactures and markets a broad range of branded and non-branded generic pharmaceutical products across the US, the MENA region, and Europe.